Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biocartis and Hospital del Mar Join Forces

Published: Monday, October 21, 2013
Last Updated: Sunday, October 20, 2013
Bookmark and Share
License agreement to develop diagnostic colon cancer test.

Biocartis and Hospital del Mar have announced their license agreement on the EGFR biomarker for colon cancer.

This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalized therapy.

Innovative platforms and tests for cancer diagnosis
Biocartis is active in molecular diagnostics and develops innovative diagnostic platforms, which allow for efficient disease detection. Biocartis also develops a wide range of clinically relevant tests for various therapeutic areas with a primary focus on cancer diagnosis.

EGFR: new biomarker for colon cancer
Recently Dr Montagut and her team (Dr Albanell’s department of Medical Oncology, Hospital del Mar) showed that colon cancer patients with an S492R-mutation in the EGFR (Epidermal Growth Factor Receptor) can’t be helped with the colon cancer drug cetuximab.

The EGFR mutation makes the tumours resistant to this treatment, whilst they remain sensitive to treatment with panitumumab. These results were published in the leading scientific journal Nature Medicine.

Rapid diagnosis results in personalized therapy
"Our agreement with Biocartis represents a crucial step in translating our relevant scientific findings to benefit the patient,” according to Clara Montagut, associated doctor, Oncology department, Hospital del Mar and researcher at the IMIM (Hospital del Mar Medical Research Institute).

The collaboration with Hospital del Mar enables Biocartis to develop a colon cancer test for a fast and accurate detection of the EGFR mutation.

"This new biomarker enables us to develop a unique combination of tests for the detection of colon cancer, which can be analyzed on our state-of-the-art molecular diagnostic platforms," added Geert Maertens, Chief Scientific Officer at Biocartis.

Maertens continued, “The detection of this biomarker in colon cancer patients ensures that personalized therapy can be applied faster and more efficiently.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Invetech and Biocartis Announce Biomarker Collaboration
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.
Wednesday, April 16, 2014
Biocartis and VIB Join Forces
Company will develop a new CRC assay for MSI biomarker detection.
Monday, December 09, 2013
Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Custom Tuning Knobs to Turn Off Any Gene
Factory managers can improve productivity by telling workers to speed up, slow down or stop doing tangential tasks while assembling widgets. Unfortunately for synthetic biologists attempting to produce pharmaceuticals, microbes don’t respond to direction like human personnel.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Genetically Mapping the Most Lethal E.Coli Strains
New approach could lead to fewer deaths, and new treatments.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!